Pfizer’s $11 billion Array purchase shows oncology assets continue to drive pharma transactions
The world’s largest life sciences company demonstrates that it is still a major presence in the M&A landscape, despite its stated focus on organic growth.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.